Renalytix plc

Company Profile

Company website
Sector
Medical Equipment and Services (Medical Equipment)
Description

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Investor Access

30 Nov
Event information

The company will hold a corresponding conference call and live webcast, reporting its first quarter fiscal year 2023 financial results at 1:30pm on Wednesday, November 30, 2022.

To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Venue
Online
Time
Wednesday 30th November 2022 at 1:30pm
Financial Calendar
 Event Date
Year End30 June
Half  Year End31 December
Preliminary Results*October
Interim Results*March
AGM*December

* Months based on previous announcements of this kind